Influence of Myocardial Viability and Regional Perfusion on Cardiac Function of Patients with Myocardial Infarction after Percutaneous Coronary Intervention Therapy_West China Medical Journal

Authors：

YiminuerAhemaitijiang ,  PENG Hui

Department of Cardiology, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang 830054, P. R. China;

Corresponding author：

PENG Hui, Email: ylmn0180@163.com

Keywords：

存活心肌; 急性心肌梗死; 心功能

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　探讨急性心肌梗死冠状动脉介入治疗（PCI）术后患者梗死区心肌存活性对左室重构及功能的影响。方法　2006年2月－2010年12月208例急性心肌梗死急诊PCI术后的患者接受静息状态下18氟-脱氧葡萄正电子断层显像进行心肌代谢显像检查，根据基线梗死区心肌有无存活分为两组，同时进行超声心动图检查，评价左室壁运动、左室射血分数，左室舒张末内径、左房内径及舒张期二尖瓣血流速度峰值的比值。血运重建术后12个月随访超声心动图，观察梗死区心肌存活状态对于左室重构以及心功能的影响。结果　PCI术后12个月，有存活心肌组左室射血分数（46.7 ± 6.98）%高于无存活心肌组（45.1 ± 7.12）%，两组差异有统计学意义（P＜0.01），有存活心肌组左室舒张末期内径（53.17 ± 3.89） mm小于无存活心肌组（55.46 ± 4.75） mm，两组差异有统计学意义（P＜0.05）。左房内径及舒张期二尖瓣血流速度峰值的比值两组随访时均无明显变化。结论　急性心肌梗死行PCI治疗后的患者，在有存活心肌的情况下，心功能改善明显；而梗死区无心肌存活的患者，12个月后，心功能减低，左室重构更加明显。

Citation： YiminuerAhemaitijiang,PENG Hui. Influence of Myocardial Viability and Regional Perfusion on Cardiac Function of Patients with Myocardial Infarction after Percutaneous Coronary Intervention Therapy. West China Medical Journal, 2012, 27(8): 1126-1128. doi: Copy

1.	Machac J. Cardiac positron emission tomography imaging[J]. Semin Nucl Med, 2005, 35(1): 17-36.
2.	Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis[J]. J Am Coll Cardiol, 2002, 39(7): 1151-1158.
3.	Kudo T. Metabolic imaging using PET[J]. Eur J Nucl Med Mol Imaging, 2007, 34(Suppl 1): S49-S61.
4.	Gimelli A, Rossi G, Landi P, et al. Stress/rest myocardial perfusion abnormalities by gated SPECT: still the best predictor of cardiac events in stable ischemic heart disease[J]. J Nucl Med, 2009, 50(4): 546-553.
5.	Stirrup J, Maenhout A, Wechalekar K, et al. Radionuclide imaging in ischaemic heart failure[J]. Br Med Bull, 2009, 92: 43-59.
6.	Beanlands R, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2)[J]. J Am Coll Cardiol, 2007, 50(20): 2002-2012.
7.	Bax RH, van JJ, Veldhuisen DJ, et al. Prediction of functional recovery after revascularization in patients with chronic ischaemic left ventricular dysfunction:head-to-head comparison between 99mTcsestamibi/18F-FDG DISA SPECT and 13N-ammonia/18F-FDG PET[J]. Eur J Nucl Med Mol Imaging, 2006, 33(6): 716-723.
8.	Zhang X, Liu XJ, Wu Q, et al. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (18)F-FDG PET[J]. J Nucl Med, 2001, 42(8): 1166-1173.
9.	Toyama T, Hoshizaki H, Seki R, et al. Evaluation of myocardial viability following acute myocardial infarction using 201Tl SPECT after thallium-glucose-insulin infusion--comparison with 18F-FDG positron emission tomography[J]. Ann Nucl Med, 2004, 18(6): 463-468.
10.	Demirkol MO. Myocardial viability testing in patients with severe left ventricular dysfunction by SPECT and PET[J]. Anadolu Kardiyol Derg, 2008, 8(Suppl 2): 60-70.
11.	Desideri A, Cortigiani L, Christen AI, et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction[J]. J Am Coll Cardiol, 2005, 46(7): 1264-1269.
12.	Chareonthaitawee P, Gersh BJ, Araoz PA, et al. Revascularization in severe left ventricular dysfunction: the role of viability testing [J]. J Am Coll Cardiol, 2005, 46(4): 567-574.

1. 　Machac J. Cardiac positron emission tomography imaging[J]. Semin Nucl Med, 2005, 35(1): 17-36.
2. 　Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis[J]. J Am Coll Cardiol, 2002, 39(7): 1151-1158.
3. 　Kudo T. Metabolic imaging using PET[J]. Eur J Nucl Med Mol Imaging, 2007, 34(Suppl 1): S49-S61.
4. 　Gimelli A, Rossi G, Landi P, et al. Stress/rest myocardial perfusion abnormalities by gated SPECT: still the best predictor of cardiac events in stable ischemic heart disease[J]. J Nucl Med, 2009, 50(4): 546-553.
5. 　Stirrup J, Maenhout A, Wechalekar K, et al. Radionuclide imaging in ischaemic heart failure[J]. Br Med Bull, 2009, 92: 43-59.
6. 　Beanlands R, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2)[J]. J Am Coll Cardiol, 2007, 50(20): 2002-2012.
7. 　Bax RH, van JJ, Veldhuisen DJ, et al. Prediction of functional recovery after revascularization in patients with chronic ischaemic left ventricular dysfunction:head-to-head comparison between 99mTcsestamibi/18F-FDG DISA SPECT and 13N-ammonia/18F-FDG PET[J]. Eur J Nucl Med Mol Imaging, 2006, 33(6): 716-723.
8. 　Zhang X, Liu XJ, Wu Q, et al. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (18)F-FDG PET[J]. J Nucl Med, 2001, 42(8): 1166-1173.
9. 　Toyama T, Hoshizaki H, Seki R, et al. Evaluation of myocardial viability following acute myocardial infarction using 201Tl SPECT after thallium-glucose-insulin infusion--comparison with 18F-FDG positron emission tomography[J]. Ann Nucl Med, 2004, 18(6): 463-468.
10. 　Demirkol MO. Myocardial viability testing in patients with severe left ventricular dysfunction by SPECT and PET[J]. Anadolu Kardiyol Derg, 2008, 8(Suppl 2): 60-70.
11. 　Desideri A, Cortigiani L, Christen AI, et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction[J]. J Am Coll Cardiol, 2005, 46(7): 1264-1269.
12. 　Chareonthaitawee P, Gersh BJ, Araoz PA, et al. Revascularization in severe left ventricular dysfunction: the role of viability testing [J]. J Am Coll Cardiol, 2005, 46(4): 567-574.

West China Medical Journal

Influence of Myocardial Viability and Regional Perfusion on Cardiac Function of Patients with Myocardial Infarction after Percutaneous Coronary Intervention Therapy

Abstract Full text Figures/Tables Video References Cited by

Format

Content